This is the authors' abstract. We don't add key points for this paper.
Key Points Shingrix is poorly immunogenic following allogeneic hematopoietic cell transplantation independent of age, CD4, and B-cell recovery. In hematopoietic cell transplantation recipients with antibody response to the vaccine, varicella zoster virus reactivation risk is not null.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Camargo et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: